Several novel therapies for castration-resistant prostate cancer (CRPC) have been approved with randomized phase III studies with continuing observational research either planned or ongoing.

Most prostate cancers eventually stop responding to androgen deprivation therapy (ADT). At this time, the cancers usually are metastatic, meaning the cancer has spread to distant parts of the body.

In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City, reviewed the TALAPRO-2 trial's implications for frontline treatment ...

Factors affecting long-term outcomes after postchemotherapy surgery in patients with nonseminomatous germ cell tumors of the mediastinum. Epidermal growth factor receptor (EGFR) targeted therapy in ...